Company Registration No. 04214826 (England and Wales)
INSIGHT MEDICAL WRITING LIMITED
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021
PAGES FOR FILING WITH REGISTRAR
INSIGHT MEDICAL WRITING LIMITED
COMPANY INFORMATION
Directors
Mr R M Traynor
(Appointed 7 June 2021)
Mr M A Schemick
(Appointed 7 June 2021)
Mr R J Wilson
(Appointed 7 June 2021)
Secretary
Mr R M Traynor
Company number
04214826
Registered office
B4 Danebrook Court Oxford Office Village
Langford Lane
Kidlington
Oxon
OX5 1LQ
Auditor
Saffery Champness LLP
Trinity
John Dalton Street
Manchester
M2 6HY
INSIGHT MEDICAL WRITING LIMITED
CONTENTS
Page
Independent auditor's report
1 - 3
Profit and loss account
4
Balance sheet
5
Notes to the financial statements
6 - 12
INSIGHT MEDICAL WRITING LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBER OF INSIGHT MEDICAL WRITING LIMITED
- 1 -
Opinion
We have audited the financial statements of Insight Medical Writing Limited (the 'company') for the period ended 31 December 2021 which comprise the profit and loss account, the balance sheet and notes to the financial statements, including significant accounting policies.
The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102
The Financial Reporting Standard applicable in the UK and Republic of Ireland
(United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
-
give a true and fair view of the state of the company's affairs as at 31 December 2021 and of its profit for the period then ended;
-
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the
Auditor's
responsibilities for the audit of the
financial statements
section of our report. We are independent of the
company
in accordance with the ethical requirements that are relevant to our audit of the
financial statements
in the UK, including the FRC’s Ethical Standard
, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit
:
-
the information given in the directors'
r
eport for the financial period for which the financial statements are prepared is consistent with the financial statements
; and
-
the directors' report has been prepared in accordance with applicable legal requirements.
INSIGHT MEDICAL WRITING LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBER OF INSIGHT MEDICAL WRITING LIMITED
- 2 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identifie
d
material misstatements in the directors'
r
eport
.
We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
-
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
-
the financial statements are not in agreement with the accounting records and returns; or
-
certain disclosures of
remuneration specified by law are not made; or
-
we have not received all the information and explanations we require for our audit; or
-
the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the directors' report and take advantage of the small companies exemption from the requirement to prepare a strategic report.
Responsibilities of directors
As explained more fully in the directors'
r
esponsibilities
s
tatement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of
financial statements
that are free from material misstatement, whether due to fraud or error. In preparing the
financial statements
, the
directors are
responsible for assessing the company
'
s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the
directors
either
intend
to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the
financial statements
as a whole are free from material misstatement, whether due to fraud or error, and to issue an
auditor's
report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with
ISAs (UK)
will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these
financial statements
.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below
.
Identifying and assessing risks related to irregularities:
We assessed the susceptibility of the group and parent company’s financial statements to material misstatement and how fraud might occur, including through discussions with the directors, discussions within our audit team planning meeting, updating our record of internal controls and ensuring these controls operated as intended. We evaluated possible incentives and opportunities for fraudulent manipulation of the financial statements. We identified laws and regulations that are of significance in the context of the group and parent company by discussions with directors and by updating our understanding of the sector in which the group and parent company operate.
Laws and regulations of direct significance in the context of the group and parent company include The Companies Act 2006, and UK Tax legislation.
INSIGHT MEDICAL WRITING LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBER OF INSIGHT MEDICAL WRITING LIMITED
- 3 -
Audit response to risks identified
We considered the extent of compliance with these laws and regulations as part of our audit procedures on the related financial statement items including a review of group and parent company financial statement disclosures. We reviewed the parent company’s records of breaches of laws and regulations, minutes of meetings and correspondence with relevant authorities to identify potential material misstatements arising. We discussed the parent company’s policies and procedures for compliance with laws and regulations with members of management responsible for compliance.
During the planning meeting with the audit team, the engagement partner drew attention to the key areas which might involve non-compliance with laws and regulations or fraud. We enquired of management whether they were aware of any instances of non-compliance with laws and regulations or knowledge of any actual, suspected or alleged fraud. We addressed the risk of fraud through management override of controls by testing the appropriateness of journal entries and identifying any significant transactions that were unusual or outside the normal course of business. We assessed whether judgements made in making accounting estimates gave rise to a possible indication of management bias. At the completion stage of the audit, the engagement partner’s review included ensuring that the team had approached their work with appropriate professional scepticism and thus the capacity to identify non-compliance with laws and regulations and fraud.
There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.
A further description of our responsibilities is available on the Financial Reporting Council’s website at:
www.frc.org.uk/auditorsresponsibilities
. This description forms part of our auditor’s report.
Other matters which we are required to address
The corresponding comparative figures are unaudited.
This report is made solely to the company's member in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's member those matters we are required to state to the member in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's member for our audit work, for this report, or for the opinions we have formed.
Simon Kite BSc FCA (Senior Statutory Auditor)
For and on behalf of Saffery Champness LLP
22 September 2022
Statutory Auditor
Trinity
John Dalton Street
Manchester
M2 6HY
INSIGHT MEDICAL WRITING LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE PERIOD ENDED 31 DECEMBER 2021
- 4 -
Period
Year
ended
ended
31 December
6 June
2021
2021
£
£
Turnover
3,145,485
5,230,116
Cost of sales
(2,371,830)
(2,986,340)
Gross profit
773,655
2,243,776
Administrative expenses
(237,418)
(590,615)
Other operating income
8,410
15,633
Operating profit
544,647
1,668,794
Interest receivable and similar income
1,218
Interest payable and similar expenses
(31)
(65,714)
Profit before taxation
544,616
1,604,298
Tax on profit
(100,466)
(312,596)
Profit for the financial period
444,150
1,291,702
INSIGHT MEDICAL WRITING LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2021
31 December 2021
- 5 -
2021
2021
Notes
£
£
£
£
Fixed assets
Tangible assets
5
27,320
66,122
Investments
6
23,994
23,994
51,314
90,116
Current assets
Stocks
675,061
766,844
Debtors
8
3,383,857
3,030,899
Cash at bank and in hand
2,360,525
2,128,025
6,419,443
5,925,768
Creditors: amounts falling due within one year
9
(1,030,165)
(998,311)
Net current assets
5,389,278
4,927,457
Total assets less current liabilities
5,440,592
5,017,573
Provisions for liabilities
8,807
(12,324)
Net assets
5,449,399
5,005,249
Capital and reserves
Called up share capital
10
2,205
2,205
Profit and loss reserves
5,447,194
5,003,044
Total equity
5,449,399
5,005,249
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors and authorised for issue on 22 September 2022 and are signed on its behalf by:
Mr R J Wilson
Director
Company Registration No. 04214826
INSIGHT MEDICAL WRITING LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2021
- 6 -
1
Accounting policies
Company information
Insight Medical Writing Limited is a
private
company
limited by shares
incorporated in
England and Wales
.
The registered office is
B4 Danebrook Court Oxford Office Village, Langford Lane, Kidlington, Oxon, OX5 1LQ.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in
sterling
, which is the functional currency of the company.
Monetary a
mounts
in these financial statements are
rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
A
true
t the time of approving the financial statements
,
t
he directors have a reasonable expectation that the
company
has adequate resources to continue in operational existence for the foreseeable future. Thus
t
he directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Reporting period
The entity's financial statements have been prepared for the period ending 31 December 2021, in order to align with the company group accounts. Therefore, it should be noted comparative amounts presented in the financial statements are not entirely comparable.
1.4
Turnover
Turnover comprises the fair value of the consideration received or receivable for the sale of
goods
and provision of services in the ordinary course of the company’s activities. Turnover is
shown net of
sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.
1.5
Research and development expenditure
Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated
.
1.6
Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date
where
it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the
fair
value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.
INSIGHT MEDICAL WRITING LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 7 -
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Development costs
These are fully depreciated
1.7
Tangible fixed assets
Tangible assets are stated in the statement of financial position at cost, less any subsequent
accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their
acquisition
and installation.
Depreciation is charged so as to write off the cost of assets, other than land and properties
under
construction over their estimated useful lives, as follows:
Leasehold improvements
Straight Line 10%
Fixtures and fittings
Reducing Balance 25%
Office Equipment
Reducing Balance 25%
Motor vehicles
Reducing Balance 25%
1.8
Investment properties
Depreciation is not provided for on freehold property as it is reviewed for impairment on an
annual
basis
.
A subsidiary is an entity controlled by the company
. Control is
the power to govern the financial and operating policies of
the
entity so as to obtain benefits from its activities.
1.9
Borrowing costs related to fixed assets
Interest-bearing borrowings are initially recorded at fair value, net of transaction costs.
Interest
-
bearing borrowings are subsequently carried at amortised cost, with the difference between
the proceeds, net of transaction costs, and the amount due on redemption being recognised as a
charge to the Statement of Comprehensive Income over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest
payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to
defer
settlement of the liability for at least twelve months after the reporting date.
1.10
Impairment of fixed assets
At each reporting
period
end date, the
company
reviews the carrying amounts of its tangible
and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the
company
estimates the recoverable amount of the cash-generating unit to which the asset belongs.
1.11
Work in progress
Work in progress represents the value of unbilled direct labour costs as assessed for
impairment.
1.12
Cash and cash equivalents
Cash and cash equivalents
are basic financial assets
and
include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
INSIGHT MEDICAL WRITING LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 8 -
1.13
Financial instruments
Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions of the financial instrument.
Basic financial assets
Debtors do not carry interest and are stated at their nominal value. Appropriate allowances for estimated irrecoverable amounts are recognised in the Profit and Loss account when there is objective evidence that the asset is impaired.
Basic financial liabilities
Creditors are not interest bearing and are included at their nominal value.
1.14
Equity instruments
Investments in equity shares which are publicly traded or where the fair value can be measured
reliably are initially measured at fair value, with changes in fair value recognised in profit or loss.
Investments in equity shares which are not publicly traded and where fair value cannot be
measured
reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective
interest method. Dividends on equity securities are recognised in income when receivable.
1.15
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the
profit and loss account
because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The
company’s
liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the
Statement of Comprehensive Income
, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the
company
has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
INSIGHT MEDICAL WRITING LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 9 -
1.16
Retirement benefits
A defined contribution plan is a pension plan under which fixed contributions are paid into a
pension
fund and the company has no legal or constructive obligation to pay further
contributions even if the
fund does not hold sufficient assets to pay all employees the benefits relating to employee service in
the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they
are due. If contribution payments exceed the contribution due for service, the excess is
recognised as
a prepayment.
1.17
Leases
Leases in which substantially all the risks and rewards of ownership are retained by the lessor
are
classified as operating leases. Payments made under operating leases are charged to profit or loss on
a straight-line basis over the period of the lease.
1.18
Government grants
Government grants are recognised at the fair value of the asset receive
d
or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.
A grant that specifies performance conditions is recognised in income when the performance conditions are met
. Where a
grant does not specify performance conditions
it
is recognised in income when the proceeds are received or receivable
. A grant received before the recognition criteria are satisfied is recognised as a liability.
1.19
Foreign exchange
Transactions in foreign currencies are initially recorded at the functional currency rate prevailing
at the
date of the transaction. Monetary assets and liabilities denominated in foreign currencies
are
retranslated into the respective functional currency of the entity at the rates prevailing on the
reporting
period date. Non-monetary items carried at fair value that are denominated in foreign
currencies are
retranslated at the rate on the date when the fair value is re-measured.
Non-monetary items measured in terms of historical cost in a foreign currency are not
retranslated.
2
Auditor's remuneration
2021
2021
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the company
21,000
3
Employees
The average monthly number of persons (including directors) employed by the company during the period was:
2021
2021
Number
Number
Total
26
31
INSIGHT MEDICAL WRITING LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2021
- 10 -
4
Intangible fixed assets
Development costs
£
Cost
At 7 June 2021 and 31 December 2021
16,000
Amortisation and impairment
At 7 June 2021 and 31 December 2021
16,000
Carrying amount
At 31 December 2021
At 6 June 2021
5
Tangible fixed assets
Leasehold improvements
Fixtures and fittings
Office Equipment
Motor vehicles
Total
£
£
£
£
£
Cost
At 7 June 2021
5,878
81,564
104,222
3,100
194,764
Additions
4,944
4,944
Disposals
(5,061)
(91,643)
(96,704)
At 31 December 2021
5,878
76,503
17,523
3,100
103,004
Depreciation and impairment
At 7 June 2021
2,312
60,214
63,016
3,100
128,642
Depreciation charged in the period
333
3,083
6,454
9,870
Eliminated in respect of disposals
(3,585)
(59,243)
(62,828)
At 31 December 2021
2,645
59,712
10,227
3,100
75,684
Carrying amount
At 31 December 2021
3,233
16,791
7,296
27,320
At 6 June 2021
3,566
21,350
41,206
66,122
6
Fixed asset investments
2021
2021
£
£
Shares in group undertakings and participating interests
23,994
23,994
INSIGHT MEDICAL WRITING LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2021
- 11 -
7
Subsidiaries
Details of the company's subsidiaries at 31 December 2021 are as follows:
Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
Insight PV & Consulting
GmbH
Leipziger Platz 15
10117
Berlin
Germany
Pharmacovigilance & regulatory advisory
services
Ordinary
100.00
8
Debtors
2021
2021
Amounts falling due within one year:
£
£
Trade debtors
2,175,083
937,727
Amounts owed by group undertakings
1,151,212
218,304
Other debtors
57,562
1,874,868
3,383,857
3,030,899
9
Creditors: amounts falling due within one year
2021
2021
£
£
Bank loans
1,444
Trade creditors
102,902
164,903
Taxation and social security
486,399
351,338
Other creditors
440,864
480,626
1,030,165
998,311
10
Called up share capital
2021
2021
2021
2021
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A of £1 each
80
80
80
80
Ordinary B of £1 each
100
100
100
100
Ordinary C of £1 each
2,025
2,025
2,025
2,025
2,205
2,205
2,205
2,205
12
Related party transactions
The Company is a wholly owned subsidiary of Certara UK Limited and has taken advantage of the available exemption conferred by section 33.1A of FRS 102 not to disclose transactions with fellow wholly owned group members.
INSIGHT MEDICAL WRITING LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2021
- 12 -
13
Parent company
The Company's immediate parent undertaking group is Certara UK Holdings Limited, whose registered address is 6th Floor, One London Wall, London, EC2Y 5EB.
The Company's ultimate parent company and
ultimate controlling party is Certara Inc. which is
incorporated in the USA.
A copy of Certara Inc. group financial statements can be obtained from 100 Overlook Center, Suite 101, Princeton, NJ 08540 USA.
2021-12-31
2021-06-07
false
22 September 2022
CCH Software
CCH Accounts Production 2022.200
Medical human health activities
Mr M A Schemick
Mr R J Wilson
Mr R J Wilson
Mr R M Traynor
04214826
2021-06-07
2021-12-31
04214826
bus:CompanySecretaryDirector1
2021-06-07
2021-12-31
04214826
bus:Director1
2021-06-07
2021-12-31
04214826
bus:Director2
2021-06-07
2021-12-31
04214826
bus:CompanySecretary1
2021-06-07
2021-12-31
04214826
bus:Director3
2021-06-07
2021-12-31
04214826
bus:RegisteredOffice
2021-06-07
2021-12-31
04214826
2021-12-31
04214826
2020-07-01
2021-06-06
04214826
2021-06-06
04214826
core:LandBuildings
core:LeasedAssetsHeldAsLessee
2021-12-31
04214826
core:FurnitureFittings
2021-12-31
04214826
core:ComputerEquipment
2021-12-31
04214826
core:MotorVehicles
2021-12-31
04214826
core:LandBuildings
core:LeasedAssetsHeldAsLessee
2021-06-06
04214826
core:FurnitureFittings
2021-06-06
04214826
core:ComputerEquipment
2021-06-06
04214826
core:MotorVehicles
2021-06-06
04214826
core:CurrentFinancialInstruments
core:WithinOneYear
2021-12-31
04214826
core:CurrentFinancialInstruments
core:WithinOneYear
2021-06-06
04214826
core:CurrentFinancialInstruments
2021-12-31
04214826
core:CurrentFinancialInstruments
2021-06-06
04214826
core:ShareCapital
2021-12-31
04214826
core:ShareCapital
2021-06-06
04214826
core:RetainedEarningsAccumulatedLosses
2021-12-31
04214826
core:RetainedEarningsAccumulatedLosses
2021-06-06
04214826
core:ShareCapitalOrdinaryShares
2021-12-31
04214826
core:ShareCapitalOrdinaryShares
2021-06-06
04214826
core:IntangibleAssetsOtherThanGoodwill
2021-06-07
2021-12-31
04214826
core:DevelopmentCostsCapitalisedDevelopmentExpenditure
2021-06-07
2021-12-31
04214826
core:LandBuildings
core:LongLeaseholdAssets
2021-06-07
2021-12-31
04214826
core:FurnitureFittings
2021-06-07
2021-12-31
04214826
core:ComputerEquipment
2021-06-07
2021-12-31
04214826
core:MotorVehicles
2021-06-07
2021-12-31
04214826
core:DevelopmentCostsCapitalisedDevelopmentExpenditure
2021-06-06
04214826
core:DevelopmentCostsCapitalisedDevelopmentExpenditure
2021-12-31
04214826
core:DevelopmentCostsCapitalisedDevelopmentExpenditure
2021-06-06
04214826
core:LandBuildings
core:LeasedAssetsHeldAsLessee
2021-06-06
04214826
core:FurnitureFittings
2021-06-06
04214826
core:ComputerEquipment
2021-06-06
04214826
core:MotorVehicles
2021-06-06
04214826
2021-06-06
04214826
core:LandBuildings
core:LeasedAssetsHeldAsLessee
2021-06-07
2021-12-31
04214826
core:Subsidiary1
2021-06-07
2021-12-31
04214826
core:Subsidiary1
1
2021-06-07
2021-12-31
04214826
core:WithinOneYear
2021-12-31
04214826
core:WithinOneYear
2021-06-06
04214826
bus:PrivateLimitedCompanyLtd
2021-06-07
2021-12-31
04214826
bus:SmallCompaniesRegimeForAccounts
2021-06-07
2021-12-31
04214826
bus:FRS102
2021-06-07
2021-12-31
04214826
bus:Audited
2021-06-07
2021-12-31
04214826
bus:FullAccounts
2021-06-07
2021-12-31
xbrli:pure
xbrli:shares
iso4217:GBP